SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]
SEC Accession No. 0000950170-24-059488
Filing Date
2024-05-14
Accepted
2024-05-14 16:01:19
Documents
13
Period of Report
2023-12-31

Document Format Files

Seq Description Document Type Size
1 10-K/A antx-20231231.htm   iXBRL 10-K/A 101484
2 EX-31.1 antx-ex31_1.htm EX-31.1 15229
3 EX-31.2 antx-ex31_2.htm EX-31.2 15002
  Complete submission text file 0000950170-24-059488.txt   1621637

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT antx-20231231.xsd EX-101.SCH 939105
16 EXTRACTED XBRL INSTANCE DOCUMENT antx-20231231_htm.xml XML 9498
Mailing Address 1800 EL CAMINO REAL, SUITE D MENLO PARK CA 94027
Business Address 1800 EL CAMINO REAL, SUITE D MENLO PARK CA 94027 (650) 331-9090
AN2 Therapeutics, Inc. (Filer) CIK: 0001880438 (see all company filings)

IRS No.: 820606654 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K/A | Act: 34 | File No.: 001-41331 | Film No.: 24944081
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)